Kurumi Taniguchi

Kurumi Taniguchi

Auto-generated profile, based on publicly available information

Kurumi Taniguchi

Department of Food Science and Nutrition, Nara Women’s University, Kita-Uoya Nishimachi, Nara 630-8506, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2022 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
SYSayuri Yoshikawa
Sayuri Yoshikawa
KTKurumi Taniguchi
Kurumi Taniguchi
HSHaruka Sawamura
Haruka Sawamura
YIYuka Ikeda
Yuka Ikeda
ATAi Tsuji
Ai Tsuji
SMSatoru Matsuda
Satoru Matsuda
Among the malignant tumors in the central nervous system (CNS), glioma is the most challenging tumor to the public society, which accounts for the majority of intracranial malignant tumors with impaired brain function. In general, conventional therapies are still unable to provide an effective cure. However, novel immunotherapies have changed the treatment scene giving patients a greater potential to attain long term survival, improved quality of life. Having shown favorable results in solid tumors, those therapies are now at a cancer research hotspot, which could even shrink the growth of glioma cells without causing severe complications. However, it is important to recognize that the therapy may be occasionally associated with noteworthy adverse action called immune-related adverse events (IRAEs) which have emerged as a potential limitation of the therapy. Multiple classes of mediators have been developed to enhance the ability of immune system to target malignant tumors including glioma but may also be associated with the IRAEs. In addition, it is probable that it would take long time after the therapy to exhibit severe immune-related disorders. Gut microbiota could play an integral role in optimal immune development and/or appropriate function for the cancer therapy, which is a vital component of the multidirectional communication between immune system, brain, and gut, also known as gut-brain-immune axis. Here, we show the potential effects of the gut-brain-immune axis based on an “engram theory” for the innovative treatment of IRAEs.

30 June 2021 in Exploration of Medicine
Verified
Journal Article
Open access
PDF file
YIYuka Ikeda
Yuka Ikeda
KTKurumi Taniguchi
Kurumi Taniguchi
SYSayuri Yoshikawa
Sayuri Yoshikawa
HSHaruka Sawamura
Haruka Sawamura
ATAi Tsuji
Ai Tsuji
SMSatoru Matsuda
Satoru Matsuda
Inflammatory bowel disease (IBD) is a multifactorial chronic disease. Patients with IBD have an increased risk of developing colorectal cancer which has become a major health concern. IBD might exert a role of engrams for making the condition of specific inflammation in the gut. Dysregulation of immune cells induced by the command of engrams might be crucial in the pathogenesis of damages in gut epithelium. The anti-proliferative (APRO) family of anti-proliferative proteins characterized by immediate early responsive gene-products that might be involved in the machinery of the carcinogenesis in IBD. Herein, it is suggested that some probiotics with specific bacteria could prevent the development and/or progression of the IBD related tumors. In addition, consideration regarding the application of studying APRO family proteins for the comprehension of IBD related tumors has been presented. It is hypothesized that overexpression of Tob1, a member of APRO family proteins, in the epithelium of IBD could suppress the function of adjacent cytotoxic immune cells possibly via the paracrine signaling.

30 June 2023 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
ATAi Tsuji
Ai Tsuji
SYSayuri Yoshikawa
Sayuri Yoshikawa
SMSae Morikawa
Sae Morikawa
YIYuka Ikeda
Yuka Ikeda
KTKurumi Taniguchi
Kurumi Taniguchi
SMSatoru Matsuda
Satoru Matsuda
Immunotherapy strategies targeting immune checkpoint molecules such as programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) are revolutionizing oncology. However, its effectiveness is limited in part due to the loss of effector cytotoxic T lymphocytes. Interestingly, supplementation of vitamin D could abolish the repressive effect of programmed cell death-ligand 1 (PD-L1) on CD8+ T cells, which might prevent the lymphocytopenia. In addition, vitamin D signaling could contribute to the differentiation of T-regulatory (Treg) cells associated with the expression of Treg markers such as forkhead box P3 (FOXP3) and CTLA-4. Furthermore, vitamin D may be associated with the stimulation of innate immunity. Peroxisome proliferator-activated receptor (PPAR) and estrogen receptor (ESR) signaling, and even the signaling from phosphoinositide-3 kinase (PI3K)/AKT pathway could have inhibitory roles in carcinogenesis possibly via the modulation of immune checkpoint molecules. In some cases, certain small molecules including vitamin D could be a novel therapeutic modality with a promising potential for the better performance of immune checkpoint blockade cancer therapies.

24 August 2023 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
SYSayuri Yoshikawa
Sayuri Yoshikawa
KTKurumi Taniguchi
Kurumi Taniguchi
HSHaruka Sawamura
Haruka Sawamura
YIYuka Ikeda
Yuka Ikeda
TATomoko T. Asai
Tomoko T. Asai
SMSatoru Matsuda
Satoru Matsuda
Hepatocellular carcinoma (HCC) constitutes an extremely malignant form of primary liver cancer. Intricate connections linking to the immune system might be associated with the pathogenesis of HCC. M